Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000178678 | SCV000230804 | uncertain significance | not provided | 2014-12-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000765179 | SCV000896414 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000765179 | SCV002146985 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2021-07-31 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 197604). This sequence change replaces lysine with arginine at codon 3095 of the SYNE2 protein (p.Lys3095Arg). The lysine residue is weakly conserved and there is a small physicochemical difference between lysine and arginine. This variant is present in population databases (rs771325522, ExAC 0.006%). This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. |